Abstract. Vitamin C (L-ascorbic Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death, resulting in approximately 0.7 million deaths each year, and the sixth most common malignancy worldwide (1-3). The recognized risk factors for HCC are hepatic disorder associated with steatosis, cirrhosis, viral hepatitis, alcohol, chemical agents, obesity, metabolic syndrome, and so forth (4). Despite recent advances in diagnosis and treatment, the effectiveness of therapy for HCC remains unsatisfactory, and HCC has a hidden development and a poor prognosis (5, 6). Therefore, there is an urgent requirement for novel therapeutic compounds for the treatment of patients with HCC. Many animal models of hepatocarcinogenesis have been established to examine the effects of therapeutic agents. Diethylnitrosamine (DEN) is frequently used as a hepatocarcinogenic agent in rodents (1). In our experimental model, externally visible foci were observed and measured by stereomicroscopy. It has been established that DEN induces HCC in animals with a developmental course similar to that of human HCC (7). Furthermore, DEN is an indirect alkylating agent that induces the generation of reactive oxygen species (ROS), which damage DNA through oxidation (8).Senescence marker protein-30 (SMP30) is a calciumbinding protein, and its levels in the liver, kidney, and lung become significantly down-regulated with aging in an androgen-independent manner (9, 10). SMP30 plays an important role in calcium (Ca 2+ ) homeostasis (11). Ca 2+ is one of the most universal and physiologically significant signaling molecules that especially affects cell apoptosis and cell necrosis (12). Other reports have indicated that SMP30 participates in controlling the activity of antioxidant enzymes 93